The effect of klatin capsule on type 2 diabetes

Phase 3

• Conditions: Type 2 diabetes mellitus.; Type 2 diabetes mellitus without complications; E11.9

• Registration Number: IRCT20210724051965N1
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Having type 2 diabetes at least three months before enrollment
Adults over 18 years

Exclusion Criteria

Pregnancy
lactation
kidney disease
liver disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fating blood sugar. Timepoint: At the beginning of the study (before the intervention) and 60 days after intervention. Method of measurement: Biochemistry- Glucose oxidase (enzymatic method).;Hemoglobin A1c. Timepoint: At the beginning of the study (before the intervention) and 60 days after intervention. Method of measurement: Biochemistry- Calorimetry.;Cholesterol. Timepoint: At the beginning of the study (before the intervention) and 60 days after intervention. Method of measurement: Calorimetric enzymatic.;Triglyceride. Timepoint: At the beginning of the study (before the intervention) and 60 days after intervention. Method of measurement: Calorimetric enzymatic.

Secondary Outcome Measures

Name	Time	Method
Blood creatinine. Timepoint: Before the intervention and 60 days after the intervention. Method of measurement: Enzymatic.;Blood urea nitrogen. Timepoint: Before the intervention and 60 days after the intervention. Method of measurement: Calorimetric enzymatic.;Quality of Life. Timepoint: Before the intervention and 60 days after the intervention. Method of measurement: Quality of Life Assessment Questionnaire 15 questions for patients with diabetes.